Wall Street analysts expect that AC Immune SA (NASDAQ:ACIU) will report earnings of ($0.24) per share for the current fiscal quarter, according to Zacks. Two analysts have issued estimates for AC Immune’s earnings. The highest EPS estimate is ($0.20) and the lowest is ($0.26). AC Immune reported earnings per share of ($0.20) in the same quarter last year, which suggests a negative year-over-year growth rate of 20%. The company is expected to report its next earnings report on Thursday, March 19th.
According to Zacks, analysts expect that AC Immune will report full-year earnings of $0.42 per share for the current year, with EPS estimates ranging from $0.12 to $0.71. For the next financial year, analysts expect that the company will post earnings of ($0.78) per share, with EPS estimates ranging from ($0.92) to ($0.71). Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side analysts that follow AC Immune.
AC Immune (NASDAQ:ACIU) last released its earnings results on Wednesday, November 13th. The company reported $0.25 EPS for the quarter, topping the Zacks’ consensus estimate of $0.17 by $0.08. The firm had revenue of $33.90 million during the quarter, compared to the consensus estimate of $31.50 million. AC Immune had a return on equity of 19.18% and a net margin of 45.19%.
Several hedge funds have recently modified their holdings of the company. Cubist Systematic Strategies LLC purchased a new stake in shares of AC Immune in the second quarter worth about $58,000. Tower Research Capital LLC TRC acquired a new stake in AC Immune during the third quarter worth about $62,000. Appleton Partners Inc. MA acquired a new stake in AC Immune during the second quarter worth about $85,000. JPMorgan Chase & Co. raised its position in AC Immune by 20.7% during the second quarter. JPMorgan Chase & Co. now owns 18,162 shares of the company’s stock valued at $99,000 after acquiring an additional 3,113 shares in the last quarter. Finally, Athanor Capital LP purchased a new position in AC Immune during the second quarter valued at approximately $234,000. 27.81% of the stock is owned by institutional investors and hedge funds.
NASDAQ:ACIU traded up $0.59 during midday trading on Friday, hitting $8.78. The company’s stock had a trading volume of 222,617 shares, compared to its average volume of 260,155. AC Immune has a fifty-two week low of $3.25 and a fifty-two week high of $12.50. The company has a debt-to-equity ratio of 0.01, a current ratio of 22.08 and a quick ratio of 22.09. The firm has a market cap of $540.50 million, a P/E ratio of -10.71 and a beta of 0.32. The firm’s 50 day moving average is $6.53 and its 200-day moving average is $5.60.
About AC Immune
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops therapeutic and diagnostic products for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for AC Immune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AC Immune and related companies with MarketBeat.com's FREE daily email newsletter.